CN113880839A - 一种厄他培南钠粗品的合成新方法 - Google Patents
一种厄他培南钠粗品的合成新方法 Download PDFInfo
- Publication number
- CN113880839A CN113880839A CN202111283661.6A CN202111283661A CN113880839A CN 113880839 A CN113880839 A CN 113880839A CN 202111283661 A CN202111283661 A CN 202111283661A CN 113880839 A CN113880839 A CN 113880839A
- Authority
- CN
- China
- Prior art keywords
- hydrogenation
- crude product
- reaction
- ertapenem
- hydrolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012043 crude product Substances 0.000 title claims abstract description 17
- 229960002818 ertapenem sodium Drugs 0.000 title claims abstract description 10
- ZXNAQFZBWUNWJM-HRXMHBOMSA-M ertapenem sodium Chemical compound [Na+].O=C([C@H]1[NH2+]C[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C([O-])=O)=O)[C@H](O)C)NC1=CC=CC(C([O-])=O)=C1 ZXNAQFZBWUNWJM-HRXMHBOMSA-M 0.000 title claims abstract description 10
- 238000001308 synthesis method Methods 0.000 title abstract description 6
- 238000005984 hydrogenation reaction Methods 0.000 claims abstract description 26
- 239000007788 liquid Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000009833 condensation Methods 0.000 claims abstract description 15
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical group O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims abstract description 14
- 230000005494 condensation Effects 0.000 claims abstract description 14
- 229960002770 ertapenem Drugs 0.000 claims abstract description 14
- 239000012074 organic phase Substances 0.000 claims abstract description 11
- 238000002425 crystallisation Methods 0.000 claims abstract description 10
- 230000008025 crystallization Effects 0.000 claims abstract description 10
- 239000003960 organic solvent Substances 0.000 claims abstract description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 8
- 239000011780 sodium chloride Substances 0.000 claims abstract description 5
- 238000005191 phase separation Methods 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 239000012266 salt solution Substances 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000010189 synthetic method Methods 0.000 claims description 2
- 239000007859 condensation product Substances 0.000 claims 2
- 238000005406 washing Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- -1 3-carboxyphenyl Chemical group 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000003850 Dipeptidase 1 Human genes 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 description 1
- 229960004912 cilastatin Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/02—Preparation
- C07D477/06—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种厄他培南钠粗品的合成新方法。该方法简化了生产操作，提高了总收率，粗品质量符合质量要求。该方法实现了缩合物无需结晶分离，直接用于下步氢化，简化了生产操作，缩短了生产处理时间，降低了缩合物的降解，提高了粗品总收率。本发明按以下步骤进行：将培南母核MAP和厄他培南侧链投入反应釜中，反应完毕后，料液加入到一种有机溶媒和水的混合液中，调pH，经盐水洗涤后，分相，有机相直接用于下一步的氢化工序。后期按现有工艺制备即可得到符合要求的厄他培南钠粗品。
Description
技术领域
本发明涉及的一种厄他培南钠粗品的合成新方法。
背景技术
厄他培南钠(Etapenem sodium)，化学名为(4R，5S，6S)-3-[[(3S，5S)-5-[[(3-羧基苯基)氨基甲酰基]吡咯烷-3-基]硫-6-(1-羟基乙基)-4-甲基-7-氧代-1-氮杂双环[3.2.0]庚-2-烯-2-甲酸钠盐，结构式：
厄他培南为美国默克公司和阿斯利康公司共同开发的新型广谱碳青霉烯类抗生素，分别于2001年11月和2002年4月在美国和欧洲批准临床应用，2005年由默沙东公司引进我国。厄他培南具有长效、抗菌活性强和细菌耐药选择性低等特点，较其他药物具有明显的临床治疗优势，为首个被FDA批准用于社区获得性肺炎的碳青霉烯类药物，同时可用于糖尿病并发症足部感染的治疗。厄他培南是通过与青霉素结合蛋白(PBP)结合，干扰细菌细胞壁的合成，导致细菌生长繁殖受抑制，少数出现细胞溶解。厄他培南对大多数青霉素酶、头孢菌素酶和超广谱β-内酰胺酶(ESBLs)稳定，但可被金属酶水解。厄他培南对甲氧西林敏感金葡菌、肺炎链球菌、化脓性链球菌等革兰阳性菌、肠杆菌科细菌具有高度抗菌活性；嗜血杆菌属、卡他莫拉菌、脑膜炎奈瑟球菌等对本品高度敏感，但甲氧西林耐药葡萄球菌、肠球菌属、铜绿假单胞菌、不动杆菌属等细菌对本品耐药。本品对人肾脱氢肽酶-Ⅰ稳定，不需与西司他丁等联合应用。
目前的工艺均为两步法，第一步先制备出缩合物，得到缩合物结晶。第二步再氢化，制得到厄他培南粗品。过程较繁琐，耗时长，而厄他培南中间体及产品均较容易降解，导致杂质偏高，收率也较低。
发明内容
本发明提供了一种厄他培南钠粗品的合成新方法，提高了粗品总收率。
本发明的技术方案如下：
本发明提供一种厄他培南钠粗品的合成方法，含有如下步骤：
(1)将培南母核MAP和厄他培南侧链投入反应釜中，缩合反应完毕，得到缩合液；
(2)缩合液加入到一种有机溶媒和水的混合液中水解，调pH，分相；
(3)有机相经盐溶液洗涤后，分相，有机相直接用于下一步的氢化工序；
(4)氢化反应，结晶。
其中，步骤(1)反应完毕无需结晶，直接将缩合液加入到有机溶剂和水的混合物中水解，缩合物水解完毕直接进入有机相中。
其中，步骤(2)中所述水解所用的有机溶剂为乙酸甲酯、乙酸乙酯、乙酸异丙酯，乙酸丁酯，优选乙酸乙酯。
其中，步骤(3)中所述洗涤有机相的盐溶液为氯化钠溶液。
其中，上述氯化钠溶液的质量百分比为5～15％，优选6-10％，最优选为7-8％。
其中，步骤(3)中所得有机相直接用于后续氢化反应，后处理，制备厄他培南粗品，粗品质量符合要求。
其中，步骤(2)中所述水解的加水体积是缩合液体积的0.8～1.2倍，优选1倍。
其中，步骤(2)中所述水解中加入钯碳，用量为MAP重量的1％，所述钯碳是5％的钯碳。
其中，步骤(2)中所述有机溶媒为四氢呋喃，用量是缩合液体积的0.5～1倍，优选0.8倍。
其中，步骤(4)中所述氢化反应的氢化压力控制0.5～1.0MPa，优选0.8MPa
其中，步骤(4)中所述氢化反应的氢化温度为20～30摄氏度，优选25摄氏度。
其中，步骤(4)中所述氢化反应的氢化时间为1～4小时，优选2小时。
其中，步骤(4)中所述结晶，加入结晶溶剂选自四氢呋喃、丙酮、乙酸乙酯，优选丙酮。
其中，上述丙酮加入体积是氢化液体积的5～8倍，优选6倍。
上述厄他培南钠粗品的合成新方法中，有机相直接用于后续氢化反应，后处理，制备厄他培南粗品，粗品质量符合要求。
具体实施方式
实施例1厄他培南粗品的合成
向干燥洁净的250ml四口瓶中加入150mL甲基吡咯烷酮，再加入培南双环母核，(简称MAP)纯度99％20.0g(33.6mmol，1.0eq)，加入侧链16.2g(36.3mmol，1.08eq)，一次性加入9.9g(56.8mmol，1.69eq)三乙胺，控温20～25℃反应6h，得到缩合液待用。
将反缩合液倒入量筒，测量体积，按体积折算，加入等1倍体积的水和0.6倍体积的四氢呋喃，加入1g 5％的钯碳，搅拌后加入氢化釜。
控温25℃，保持氢气压力0.8MPa，氢化2小时，得到氢化液。
氢化液过滤除去钯碳，测量体积，加入6倍体积的丙酮结晶，得到白色的厄他培南粗品，纯度98.9％，水分2.1％，产品10.8g，按MAP折算重量收率54％。
Claims (10)
1.一种厄他培南钠粗品的合成方法，含有如下步骤：
(1)将培南母核MAP和厄他培南侧链投入反应釜中，缩合反应完毕，得到缩合液；
(2)缩合液加入到一种有机溶媒和水的混合液中水解，调pH，分相；
(3)有机相经盐溶液洗涤后，分相，有机相直接用于下一步的氢化工序；
(4)氢化反应，结晶。
2.如权利要求1所述的方法，其特征在于步骤(1)反应完毕无需结晶，直接将缩合液加入到有机溶剂和水的混合物中水解，缩合物水解完毕直接进入有机相中。
3.如权利要求1所述的方法，其特征在于步骤(2)中所述水解所用的有机溶剂为乙酸甲酯、乙酸乙酯、乙酸异丙酯，乙酸丁酯，优选乙酸乙酯。
4.如权利要求1所述的方法，其特征在于步骤(3)中所述盐溶液为氯化钠溶液，优选氯化钠溶液的质量百分比为5～15％，优选6-10％，最优选为7-8％。
5.如权利要求1所述的方法，其特征在于步骤(3)中所得有机相直接用于后续氢化反应。
6.如权利要求1所述的方法，其特征在于步骤(2)中水体积是缩合液体积的0.8～1.2倍，优选1倍。
7.如权利要求1所述的方法，其特征在于步骤(2)中所述水解中加入钯碳，用量为MAP重量的1％，所述钯碳是5％的钯碳。
8.如权利要求1所述的方法，其特征在于步骤(2)中所述有机溶媒为四氢呋喃，用量是缩合液体积的0.5～1倍，优选0.8倍。
9.如权利要求1所述的方法，其特征在于步骤(4)中所述氢化反应的氢化压力控制0.5～1.0MPa，优选0.8MPa，或
所述氢化反应的氢化温度为20～30℃，优选25℃，或
所述氢化反应的氢化时间为1～4小时，优选2小时。
10.如权利要求1所述的方法，其特征在于步骤(4)中所述结晶，加入结晶溶剂选自四氢呋喃、丙酮、乙酸乙酯，优选丙酮，进一步优选丙酮加入体积是氢化液体积的5～8倍，优选6倍。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111283661.6A CN113880839A (zh) | 2021-11-01 | 2021-11-01 | 一种厄他培南钠粗品的合成新方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111283661.6A CN113880839A (zh) | 2021-11-01 | 2021-11-01 | 一种厄他培南钠粗品的合成新方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113880839A true CN113880839A (zh) | 2022-01-04 |
Family
ID=79014923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111283661.6A Pending CN113880839A (zh) | 2021-11-01 | 2021-11-01 | 一种厄他培南钠粗品的合成新方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113880839A (zh) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011141847A1 (en) * | 2010-05-10 | 2011-11-17 | Orchid Chemicals And Pharmaceuticals Limited | An improved process for the preparation of meropenem |
| WO2013121279A2 (en) * | 2012-02-14 | 2013-08-22 | Aurobindo Pharma Limited | Process to prepare ertapenem |
| WO2013150550A2 (en) * | 2012-04-04 | 2013-10-10 | Orchid Chemicals & Pharmaceuticals Limited | An improved process for the preparation of carbapenem antibiotic |
| CN103524507A (zh) * | 2012-07-05 | 2014-01-22 | 天津九海医药科技有限公司 | 一种厄他培南钠盐的制备方法 |
| CN104703986A (zh) * | 2012-10-12 | 2015-06-10 | 桑多斯股份公司 | 厄他培南中间体的制备 |
| WO2015087245A1 (en) * | 2013-12-11 | 2015-06-18 | Unimark Remedies Ltd. | Process for preparation of ertapenem and salts thereof |
| CN106279175A (zh) * | 2016-08-12 | 2017-01-04 | 上海龙翔生物医药开发有限公司 | 一种厄他培南单钠盐的制备方法 |
| CN110698478A (zh) * | 2018-07-09 | 2020-01-17 | 武汉启瑞药业有限公司 | 一种厄他培南单钠盐的合成方法 |
-
2021
- 2021-11-01 CN CN202111283661.6A patent/CN113880839A/zh active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011141847A1 (en) * | 2010-05-10 | 2011-11-17 | Orchid Chemicals And Pharmaceuticals Limited | An improved process for the preparation of meropenem |
| WO2013121279A2 (en) * | 2012-02-14 | 2013-08-22 | Aurobindo Pharma Limited | Process to prepare ertapenem |
| WO2013150550A2 (en) * | 2012-04-04 | 2013-10-10 | Orchid Chemicals & Pharmaceuticals Limited | An improved process for the preparation of carbapenem antibiotic |
| CN103524507A (zh) * | 2012-07-05 | 2014-01-22 | 天津九海医药科技有限公司 | 一种厄他培南钠盐的制备方法 |
| CN104703986A (zh) * | 2012-10-12 | 2015-06-10 | 桑多斯股份公司 | 厄他培南中间体的制备 |
| WO2015087245A1 (en) * | 2013-12-11 | 2015-06-18 | Unimark Remedies Ltd. | Process for preparation of ertapenem and salts thereof |
| CN106279175A (zh) * | 2016-08-12 | 2017-01-04 | 上海龙翔生物医药开发有限公司 | 一种厄他培南单钠盐的制备方法 |
| CN110698478A (zh) * | 2018-07-09 | 2020-01-17 | 武汉启瑞药业有限公司 | 一种厄他培南单钠盐的合成方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102010426B (zh) | 一种制备头孢唑肟钠的方法 | |
| CN100497349C (zh) | 一种改进的比阿培南的制备方法 | |
| CN103347515B (zh) | 化合物及其用途 | |
| CN101121716A (zh) | 一种比阿培南的合成方法 | |
| TW201141867A (en) | Improved process for the preparation of carbapenem using carbapenem intermediates and recovery of carbapenem | |
| US4997829A (en) | Penem compounds, and use thereof | |
| CN107501268B (zh) | 一种替比培南酯及其中间体的制备方法 | |
| CN101843589A (zh) | 注射用头孢唑肟钠组合物无菌粉末 | |
| CN102558181A (zh) | 一种碳青霉烯抗生素的制备方法 | |
| CN113880839A (zh) | 一种厄他培南钠粗品的合成新方法 | |
| US4261977A (en) | Streptomycetal antibiotic | |
| CN109553626B (zh) | 一种头孢唑肟钠的精制方法 | |
| CN110423237B (zh) | 一种厄他培南钠的精制方法 | |
| CN115448930A (zh) | 氨苄西林钠的制备方法 | |
| US8822445B2 (en) | Crystalline form of carbapenem derivative or its hydrates and preparation methods and uses thereof | |
| US20130079322A1 (en) | Crystalline of carbapenem derivative or its hydrate, preparation methods and uses thereof | |
| CN110372729B (zh) | 一种氟氧头孢钠的精制方法 | |
| CN109503629B (zh) | 一种头孢唑肟酸的合成方法 | |
| CN102304129B (zh) | 一种适合工业化生产替比培南的方法 | |
| CN102731503B (zh) | 一种泰比培南的制备方法 | |
| CN102757430B (zh) | 一种替比培南的制备方法 | |
| EP2276762B1 (en) | Process for the preparation of sterile doripenem | |
| CN103588786A (zh) | 法罗培南钠水合物的提纯方法 | |
| CN104072523A (zh) | 比阿培南的制备方法 | |
| CN109535184B (zh) | 一种克拉维酸叔辛胺制备克拉维酸钾的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220104 |